Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Malignant Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00684983
What this trial is testing

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Who this might be right for
HER2 Positive Breast CarcinomaRecurrent Breast CarcinomaStage IIIB Breast Cancer AJCC v7+2 more
National Cancer Institute (NCI) 64
Testing effectiveness (Phase 2)UnknownNCT04760431
What this trial is testing

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Who this might be right for
HER2-positive Breast CancerBrain Metastases
Second Affiliated Hospital, Zhejiang University, School of Medicine 120
Not applicableLooking for participantsNCT06744465
What this trial is testing

NearWave Optical Molecular Monitoring

Who this might be right for
Breast CancerHER2-positive Breast CancerTNBC - Triple-Negative Breast Cancer+2 more
Indiana University 15
Not applicableUnknownNCT03521245
What this trial is testing

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
OmicsWay Corp. 40
Testing effectiveness (Phase 2)WithdrawnNCT00434031
What this trial is testing

CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
National Cancer Institute, Naples
Testing effectiveness (Phase 2)Looking for participantsNCT07263425
What this trial is testing

Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis

Who this might be right for
Leptomeningeal Metastasis of HER2-positive Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT04126525
What this trial is testing

Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

Who this might be right for
Breast Cancer Female
RenJi Hospital 53
Testing effectiveness (Phase 2)Looking for participantsNCT06178159
What this trial is testing

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 40
Not applicableLooking for participantsNCT06281210
What this trial is testing

Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery

Who this might be right for
Breast CancerTriple Negative Breast CancerHER2-positive Breast Cancer+1 more
European Institute of Oncology 77
Large-scale testing (Phase 3)Active Not RecruitingNCT05802225
What this trial is testing

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Biocad 398
Testing effectiveness (Phase 2)Ended earlyNCT00810017
What this trial is testing

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

Who this might be right for
HER-2 Positive Metastatic Breast Cancer
Medstar Health Research Institute 2
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06973525
What this trial is testing

This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.

Who this might be right for
HER2-positive Breast Cancer
Hebei Medical University Fourth Hospital 30
Large-scale testing (Phase 3)Not Yet RecruitingNCT07748260
What this trial is testing

De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast

Who this might be right for
HER2-positive Breast Cancer
Guangdong Provincial People's Hospital 592
Not applicableUnknownNCT03847818
What this trial is testing

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Shandong University 268
Early research (Phase 1)Study completedNCT01097460
What this trial is testing

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Who this might be right for
Breast Neoplasms
Merrimack Pharmaceuticals 16
Not applicableUnknownNCT06479460
What this trial is testing

Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients

Who this might be right for
Breast CancerNeoadjuvantHER2-positive Breast Cancer+1 more
The First Affiliated Hospital with Nanjing Medical University 50
Large-scale testing (Phase 3)Looking for participantsNCT06891833
What this trial is testing

BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 985
Not applicableNot Yet RecruitingNCT04225858
What this trial is testing

Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy

Who this might be right for
Breast CancerTriple Negative Breast CancerHER2-positive Breast Cancer+1 more
The Netherlands Cancer Institute 340
Not applicableApproved For MarketingNCT03133988
What this trial is testing

Margetuximab Expanded Access Program

Who this might be right for
HER2-positive Breast CancerHER2-positive Carcinoma
TerSera Therapeutics LLC
Not applicableLooking for participantsNCT04281641
What this trial is testing

Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Fudan University 94
Next Page